FDA peptide restrictions panel backs wider manufacturing access

An FDA-organized advisory committee voted Thursday to recommend easing FDA peptide restrictions for human use, backing wider manufacturing access for four compounds and setting up votes on three more. The recommendation is not a final agency action, but Ars Technica reported that the result follows months of pressure from Health and Human Services Secretary Robert F. Kennedy Jr., who had already signaled interest in reversing limits on peptide manufacturing by compounding pharmacies.

The committee was sharply split, according to Ars Technica. Members added after Kennedy took office supplied the decisive support for lifting the restrictions, while all members who were on the panel before Kennedy’s changes voted against the move. Ars reported that Kennedy added members in June who, except for one, had clear interests in making or selling unapproved peptides.

The vote covered four peptides, with three additional peptides scheduled for consideration Friday. No clinical, pharmacological or safety evidence of the kind Kennedy previously said would guide the review was presented at the meeting, Ars reported.

What are peptides, and why is the FDA involved?

Peptides are short chains of amino acids, usually much shorter than proteins. Some are established medicines, including insulin, while others are biological fragments with unclear effects in humans.

The FDA has approved some peptide drugs through its normal drug-review process, including insulin and newer weight-loss drugs. The contested category is different: peptides that lack sufficient evidence of safety and effectiveness but are sought by users and sellers outside the approved-drug pathway. The Biden administration had blocked their manufacture by compounding pharmacies, which prepare specialty medications for patients.

The evidentiary issue is central. Ars noted that researchers may see a peptide act on cultured cells without knowing what will happen in an intact animal or human. Drug development often fails at that stage, when effects seen in simplified systems do not translate into safe or useful treatments.

The New York Times reported that, when a committee member asked whether the FDA had ever approved something that had never been tested in humans, an FDA official said it had not. That answer could matter because the panel’s recommendation is advisory. The FDA can reject it, although doing so would put agency staff at odds with Kennedy, who oversees the department and can remove officials.

Kennedy’s role is what turns a niche regulatory question into a governance fight. Ars described Kennedy as an enthusiast for peptides and reported that he had moved earlier in the year to reopen access. The panel vote now gives that policy push formal support, but it does not resolve the question regulators usually ask first: whether the products work and whether people can use them safely.

This story draws on original reporting from Ars Technica.